To keep patients on amyloid immunotherapy safe, doctors need to be able to spot subtle signs of ARIA on MRI scans. For memory clinics that have limited experience with these therapies, this may prove ...
Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation ...
Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...
Move Over, Vial. In a new titra/news/conference-coverage/donanemab-small-tweak-titration-big-gain-safetytion protocol (bottom ...
An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...
“Bruce had a brilliant career in both academia and industry and left an indelible mark on the Alzheimer’s disease drug ...
The fifth time may be the charm for antibodies targeting tau. At the 16th Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Brussels-based UCB Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback